Replies to post #172598 on Biotech Values

[DewDiligence]

PTLA may have some problems, but not liquidity problems:

http://www.sec.gov/Archives/edgar/data/1269021/000119312514073391/d683692dex991.htm

Cash, cash equivalents and investments at December 31, 2013, totaled $319.0 million… Portola expects to end 2014 with approximately $185 million to $200 million in cash, cash equivalents and investments.

In other words, the projected 2014 cash burn is $119-134M. The Betirxaban program is consuming much of this amount.